Cargando…

Innate Cells: The Alternative Source of IL-17 in Axial and Peripheral Spondyloarthritis?

Spondyloarthritis (SpA) is a chronic inflammatory rheumatism characterized by inflammation of sacroiliac joints, peripheral joints, and spine. The Assessment of SpondyloArthritis Society describes three disease forms: axial (axSpA), peripheral, and enthesitic SpA. Each may be associated with extra-a...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosine, Nicolas, Miceli-Richard, Corinne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821711/
https://www.ncbi.nlm.nih.gov/pubmed/33488572
http://dx.doi.org/10.3389/fimmu.2020.553742
_version_ 1783639479685218304
author Rosine, Nicolas
Miceli-Richard, Corinne
author_facet Rosine, Nicolas
Miceli-Richard, Corinne
author_sort Rosine, Nicolas
collection PubMed
description Spondyloarthritis (SpA) is a chronic inflammatory rheumatism characterized by inflammation of sacroiliac joints, peripheral joints, and spine. The Assessment of SpondyloArthritis Society describes three disease forms: axial (axSpA), peripheral, and enthesitic SpA. Each may be associated with extra-articular manifestations: psoriasis, inflammatory bowel disease, and acute anterior uveitis. Genome-wide association studies performed in axSpA and psoriatic arthritis (PsA) have shown a shared genetic background, especially the interleukin 23 (IL-23)/IL-17 pathway, which suggests pathophysiological similarities. The convincing positive results of clinical trials assessing the effect of secukinumab and ixekizumab (anti-IL-17A monoclonal antibodies) in axSpA and PsA have reinforced the speculated crucial role of IL-17 in SpA. Nevertheless, and obviously unexpectedly, the differential efficacy of anti-IL-23–targeted treatments between axSpA (failure) and PsA (success) has profoundly disrupted our presumed knowledge of disease pathogeny. The cells able to secrete IL-17, their dependence on IL-23, and their respective role according to the clinical form of the disease is at the heart of the current debate to potentially explain these observed differences in efficacy of IL-23/IL-17–targeted therapy. In fact, IL-17 secretion is usually mainly related to T helper 17 lymphocytes. Nevertheless, several innate immune cells express IL-23 receptor and can produce IL-17. To what extent these alternative cell populations can produce IL-17 independent of IL-23 and their respective involvement in axSpA and PsA are the crucial scientific questions in SpA. From this viewpoint, this is a nice example of a reverse path from bedside to bench, in which the results of therapeutic trials allow for reflecting more in depth on the pathophysiology of a disease. Here we provide an overview of each innate immunity-producing IL-17 cell subset and their respective role in disease pathogeny at the current level of our knowledge.
format Online
Article
Text
id pubmed-7821711
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78217112021-01-23 Innate Cells: The Alternative Source of IL-17 in Axial and Peripheral Spondyloarthritis? Rosine, Nicolas Miceli-Richard, Corinne Front Immunol Immunology Spondyloarthritis (SpA) is a chronic inflammatory rheumatism characterized by inflammation of sacroiliac joints, peripheral joints, and spine. The Assessment of SpondyloArthritis Society describes three disease forms: axial (axSpA), peripheral, and enthesitic SpA. Each may be associated with extra-articular manifestations: psoriasis, inflammatory bowel disease, and acute anterior uveitis. Genome-wide association studies performed in axSpA and psoriatic arthritis (PsA) have shown a shared genetic background, especially the interleukin 23 (IL-23)/IL-17 pathway, which suggests pathophysiological similarities. The convincing positive results of clinical trials assessing the effect of secukinumab and ixekizumab (anti-IL-17A monoclonal antibodies) in axSpA and PsA have reinforced the speculated crucial role of IL-17 in SpA. Nevertheless, and obviously unexpectedly, the differential efficacy of anti-IL-23–targeted treatments between axSpA (failure) and PsA (success) has profoundly disrupted our presumed knowledge of disease pathogeny. The cells able to secrete IL-17, their dependence on IL-23, and their respective role according to the clinical form of the disease is at the heart of the current debate to potentially explain these observed differences in efficacy of IL-23/IL-17–targeted therapy. In fact, IL-17 secretion is usually mainly related to T helper 17 lymphocytes. Nevertheless, several innate immune cells express IL-23 receptor and can produce IL-17. To what extent these alternative cell populations can produce IL-17 independent of IL-23 and their respective involvement in axSpA and PsA are the crucial scientific questions in SpA. From this viewpoint, this is a nice example of a reverse path from bedside to bench, in which the results of therapeutic trials allow for reflecting more in depth on the pathophysiology of a disease. Here we provide an overview of each innate immunity-producing IL-17 cell subset and their respective role in disease pathogeny at the current level of our knowledge. Frontiers Media S.A. 2021-01-08 /pmc/articles/PMC7821711/ /pubmed/33488572 http://dx.doi.org/10.3389/fimmu.2020.553742 Text en Copyright © 2021 Rosine and Miceli-Richard http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Rosine, Nicolas
Miceli-Richard, Corinne
Innate Cells: The Alternative Source of IL-17 in Axial and Peripheral Spondyloarthritis?
title Innate Cells: The Alternative Source of IL-17 in Axial and Peripheral Spondyloarthritis?
title_full Innate Cells: The Alternative Source of IL-17 in Axial and Peripheral Spondyloarthritis?
title_fullStr Innate Cells: The Alternative Source of IL-17 in Axial and Peripheral Spondyloarthritis?
title_full_unstemmed Innate Cells: The Alternative Source of IL-17 in Axial and Peripheral Spondyloarthritis?
title_short Innate Cells: The Alternative Source of IL-17 in Axial and Peripheral Spondyloarthritis?
title_sort innate cells: the alternative source of il-17 in axial and peripheral spondyloarthritis?
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821711/
https://www.ncbi.nlm.nih.gov/pubmed/33488572
http://dx.doi.org/10.3389/fimmu.2020.553742
work_keys_str_mv AT rosinenicolas innatecellsthealternativesourceofil17inaxialandperipheralspondyloarthritis
AT micelirichardcorinne innatecellsthealternativesourceofil17inaxialandperipheralspondyloarthritis